Bristol-Myers Squibb: Melanoma trials

The registry lists 106 Melanoma studies with Bristol-Myers Squibb as lead sponsor. 3 are open to participants now and 42 have results posted.

Phase 1 23Phase 2 30Phase 3 23Phase 4 1No phase 35(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingNCT07492680Phase 2
• A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In IndiaNot yet recruitingNCT07459543Phase 4
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT04895709Phase 1/2
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingNCT06101134Phase 2Results posted
• A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaActive, not recruitingNCT05625399Phase 3Results posted
• A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionCompletedNCT05297565Phase 3Results posted
• A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaTerminatedNCT05002569Phase 3Results posted
• Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingNCT04099251Phase 3Results posted
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaCompletedNCT03635983Phase 3Results posted
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingNCT03470922Phase 2/3Results posted
• A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedNCT03400332Phase 1/2Results posted
• An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaCompletedNCT03329846Phase 3Results posted
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCompletedNCT03068455Phase 3Results posted
• A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaCompletedNCT02905266Phase 3Results posted
• A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaCompletedNCT02714218Phase 3Results posted
• Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaCompletedNCT02599402Phase 3Results posted
• A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. DacarbazineCompletedNCT02545075Phase 3Results posted
• Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedNCT02388906Phase 3Results posted
• An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfCompletedNCT02320058Phase 2Results posted
• A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)CompletedNCT02156804Phase 2Results posted
• Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsCompletedNCT01990859Phase 2Results posted
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsCompletedNCT01962103Phase 1/2Results posted
• Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01927419Phase 2Results posted
• Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedNCT01844505Phase 3Results posted
• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)CompletedNCT01783938Phase 2Results posted
• Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01721772Phase 3Results posted
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedNCT01721746Phase 3Results posted
• Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaTerminatedNCT01709162Phase 2Results posted
• Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaTerminatedNCT01696045Phase 2Results posted
• Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaCompletedNCT01681212Phase 2Results posted
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results posted
• PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCompletedNCT01621490Phase 1Results posted
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg IpilimumabCompletedNCT01515189Phase 3Results posted
• Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TerminatedNCT01400451Phase 1Results posted
• Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT01024231Phase 1Results posted
• Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced MelanomaCompletedNCT00920907Phase 1Results posted
• A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaCompletedNCT00864253Phase 3Results posted
• Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, DacarbazineCompletedNCT00796991Phase 1Results posted
• Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III MelanomaCompletedNCT00636168Phase 3Results posted
• Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain MetastasesCompletedNCT00623766Phase 2Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaCompletedNCT00324155Phase 3Results posted
• A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab StudiesCompletedNCT00162123Phase 2Results posted
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3Results posted
• Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaCompletedNCT00084656Phase 2Results posted
• Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabCompletedNCT07091695
• A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With MelanomaCompletedNCT06163170
• A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnNCT05496192Phase 2
• A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic TherapyCompletedNCT05432622
• Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German DatabaseCompletedNCT05426239
• A Study of Adjuvant Melanoma Stakeholder Treatment PreferencesCompletedNCT05115006
• A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in FranceActive, not recruitingNCT04550247
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWithdrawnNCT04495010Phase 2
• A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)Active, not recruitingNCT04196452
• An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in AustraliaCompletedNCT04146324
• A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionCompletedNCT03980314Phase 1
• A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedNCT03978611Phase 1
• A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedCompletedNCT03771859
• A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the USCompletedNCT03732560
• A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced MelanomaCompletedNCT03696069
• Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced MelanomaCompletedNCT03504696
• Long Term Quality of Life in Melanoma Patients in NetherlandsCompletedNCT03450876
• Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United KingdomCompletedNCT03448497
• Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination TherapyCompletedNCT03438279
• The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in GermanyWithdrawnNCT03205722
• Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United StatesCompletedNCT03199846
• A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in JapanCompletedNCT03165422
• Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has SpreadCompletedNCT03165409
• Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab TherapyCompletedNCT02990611
• Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabCompletedNCT02935790Phase 1
• Yervoy Pregnancy Surveillance StudyWithdrawnNCT02854488
• Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology PracticeCompletedNCT02847728
• Interferon Toxicities in Melanoma TreatmentCompletedNCT02794636
• Study in Patients With Unresectable And Metastatic Melanoma: The Optimize StudyCompletedNCT02780089
• Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune DiseasesCompletedNCT02739386
• Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant MelanomaCompletedNCT02717364
• A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid TumorsCompletedNCT02516527Phase 1
• PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced MelanomaCompletedNCT02492815
• Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in TaiwanCompletedNCT02402699
• YERVOY® Risk Minimization Tool Effectiveness Evaluation SurveyCompletedNCT02224768
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaNo longer availableNCT02186249
• Expanded Access Program With Nivolumab to Treat MelanomaNo longer availableNCT02142218
• Ipilimumab 12-month Intensive Pharmacovigilance ProtocolCompletedNCT02050594
• Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic MelanomaWithdrawnNCT01933061Phase 2
• A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic MelanomaCompletedNCT01511913
• Safety Study of IL-21/Ipilimumab Combination in the Treatment of MelanomaCompletedNCT01489059Phase 1
• Phase 1 Biomarker Study of Anti-PDL-1 in Advanced MelanomaWithdrawnNCT01455103Phase 1
• Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced MelanomaCompletedNCT01245556Phase 1
• Long-term Data Collection for Subjects in MDX-010 StudiesCompletedNCT00928031
• Combination of Anti-CD137 & Ipilimumab in Patients With MelanomaWithdrawnNCT00803374Phase 1
• Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00729950Phase 1
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• Phase II, 2nd Line Melanoma - RAND MonotherapyCompletedNCT00612664Phase 2
• Compassionate Use Trial for Unresectable Melanoma With IpilimumabNo longer availableNCT00495066
• Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaWithdrawnNCT00357461Phase 2
• Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289640Phase 2
• A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289627Phase 2
• Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)CompletedNCT00261365Phase 1/2
• Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic ChemotherapyCompletedNCT00179608Phase 1